NCCN 9th Annual Congress: Hematologic Malignancies

 
 
 

 

Armored CAR T cells next on the production line

Erilyn Riley Read Article
Published: 10/28/14

Park_Jae H_MD_NCCN_2014_240_v2.jpg
Jae H. Park, MD

Chimeric antigen receptor (CAR) T cells have “remarkable” activity, according to a speaker at the NCCN 9th Annual Congress: Hematologic Malignancies. “[T]his chimera binds like an antibody, but it acts like a T cell, so it combines the best of both worlds,” said Jae H. Park, MD, of Memorial Sloan Kettering Cancer Center. He then traced the evolution of CAR T-cell design, discussed clinical trials using CD19-targed T cells, and described how investigators are working at building a better T cell. [Read Article]

Preventing cancer-related infection

Erilyn Riley Read Article
Published: 09/27/14

hand-washing_Credit_CDC_Kimberly_Smith_Christine_Ford_220.jpg
Hand washing
Credit: CDC/Kimberly Smith
and Christine Ford

Hand washing is still the single most effective method to prevent the transmission of infection, but additional measures can reduce the risk of cancer-related infections, according to a speaker at the NCCN 9th Annual Congress: Hematologic Malignancies. In her presentation, Laura Zitella, RN, of the Stanford Cancer Institute in California, discussed current recommendations for pharmacologic and non-pharmacologic infection prophylaxis. [Read Article]

Speaker offers alternatives for sustainable TKI use in CML

Erilyn Riley Read Article
Published: 09/26/14

Shah_Neil_MD_PhD_NCCN2014_strt-shrp-240.jpg
Neil P. Shah, MD, PhD

If any oncology drugs warrant a high price, BCR-ABL tyrosine kinase inhibitors (TKIs) could make a strong case, according to a speaker at the NCCN 9th Annual Congress: Hematologic Malignancies. TKIs have revolutionized the therapeutic landscape in chronic myeloid leukemia (CML), said Neil P. Shah, MD, PhD, of the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco. Five-year overall survival is 93% in CML patients treated with imatinib. [Read Article]

Split decision on role of upfront transplant in MM

Erilyn Riley Read Article
Published: 09/26/14

HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg
Preparing for transplant
Credit: Chad McNeeley

A debate on the pros and cons of upfront transplant in symptomatic multiple myeloma (MM) yielded a split decision from the audience during the NCCN 9th Annual Congress: Hematologic Malignancies. Sergio Giralt, MD, argued for upfront transplant, pointing out that long-term MM survivors have transplants upfront. Kenneth Anderson, MD, took the stance that, in the past 10 years, there has been a revolution in novel therapies that has significantly improved survival in MM. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}